Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 9, 2021, Mr. Tae Heum (Ted) Jeong provided notice of his resignation from the Board of Directors (the "Board") of NeuroBo Pharmaceuticals, Inc. (the "Company"), effective immediately. Dr. Jeong's resignation was not the result of any disagreement with the Company regarding the Company's operations, policies or practices. In connection with the resignation of Dr. Jeong, the Board reduced the size of the Board from eight members to seven members.

On January 11, 2021, Douglas J. Swirsky, a current director of the Company was elected Chairman of the Board and appointed Chairman of the Audit Committee. Mr. Jeong Gyun Oh, a current director of the Company was appointed to the Audit Committee. The Board has determined that each of Mr. Swirsky and Mr. Oh are independent in accordance with the listing standards of Nasdaq and the Company's internal policies, and that each otherwise meets all applicable requirements to serve on the Audit Committee, including the rules and regulations of the Securities and Exchange Commission ("SEC"). In addition, the Board has determined that each of Mr. Swirsky and Mr. Oh qualify as an "audit committee financial expert" pursuant to SEC rules and regulations.

On January 11, 2021, Nicola Shannon resigned as the Company's Vice President of Clinical Operations effective January 22, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses